MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • IGI Laboratories, Inc. (IG) To Launch First IGI Labeled Generic Topical Prescription Drug Products 0 comments
    Nov 6, 2012 2:32 PM | about stocks: TLGT

    Yesterday, New Jersey-based topical generic pharmaceutical company IGI Laboratories announced it will launch its first IGI labeled generic products later this year.

    The company has an extensive partnership with Medimetriks Pharmaceuticals, Inc., which is a branded specialty pharmaceutical company focused on the dermatology market. As part of this relationship, IGI serves as Medimetriks' authorized generic dealer for certain products. On Nov. 1, IGI received authorization to launch generic distribution of certain of Medimetriks' recently launched Synalar (fluocinolone acetonide) line of prescription topical products.

    IGI will work closely with Medimetriks to help ensure the successful launch of these generic topical prescription products. IGI believes this launch with its important partner is an essential component of the company's long-term strategy. The current market conditions indicate a total addressable market for the first three products of around $30 million, of which IGI expects to achieve a meaningful market share.

    Launch activity has commenced, and with the authorization to go to market, only a few steps remain before the company's first IGI labeled generic topical product is ready to launch. The company has made significant strides in finalizing the needful state licensing requirements for commercial distribution. IGI is actively negotiating its logistics agreements with the proper wholesalers and retailers, and the company additionally plans to announce its distribution partner in the near future.

    The pivot discussed in IGI's last earnings call is well underway. With this launch, the company is in motion to deliver on its promise to become a leader in the generic topical pharmaceutical market.

    IGI Laboratories is engaged in the development and manufacturing of topical formulations for the pharmaceutical, OTC, and cosmetic markets. The company's aim is to become a leading player in the generic topical prescription drug market.

    For more information, visit www.igilabs.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: TLGT
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.